I am representing Myllia Biotechnology at Single-Cell Genomics 2024 in Paris, France - thanks to Institut Imagine for hosting the event! Reach out to discuss your next #CRISPR #screening and #functional #genomics projects for drug target discovery in single cells! myllia.com

At Myllia Biotechnology, we use single-cell #CRISPR screens for target discovery in challenging cell models, e.g., primary T cells. Watch the latest #interview with Tilmann Bürckstümmer at @ELRIG_UK Drug Discovery 2024 and reach out to discuss your next CRISPR project! youtu.be/9Po9Tlvrrgk?si…

Did you know Myllia Biotechnology has a #YouTube channel? If you like, check out some of the edutainment videos we've created to showcase our single-cell #CRISPR #screening platform! Become "famyllia" with CROP-Seq (Perturb-Seq): youtu.be/8TS794MDHwg?si…

🔬 At Myllia Biotechnology, we're revolutionizing target discovery with CROP-Seq in primary human T cells: - Custom assay development - SLICE protocol for functional screening - Integration of CITE-Seq & scRNA-Seq Ready to elevate your research? Contact us via: myllia.com

Can #AI predict #CRISPR perturbation outcomes? Myllia Biotechnology's CROP-Seq dataset provides a critical resource for AI-driven #Foundation #Models of the Human Cell: CROP-Seq training datasets for AI-based foundation models of human cell biology — Myllia

📢 One month to go! Myllia Biotechnology will be at #BIOEuropeSpring 2025 in Milan, Italy! Would you like to get in touch? Meet our BD Manager Henrik Schmidt on site to explore #CRISPR-based #functional #genomics screens in primary human cells! Learn more here: myllia.com

🧬 At Myllia Biotechnology, we're pushing the boundaries of scCRISPR screens in primary human T cells. For example, we focus on scalable CROP-Seq screens to uncover key mediators of T helper cell differentiation, particularly Th2 cells! myllia.com #CRISPR #scRNASeq #TCells

A team at Myllia Biotechnology contributed one of the largest single-cell CRISPR perturbation screens published today: nature.com/articles/s4155… The lab of Wei Li developed the perturbation-response score (PS) allowing the quantification of diverse perturbation responses in single cells!

🚀 At Myllia Biotechnology, we're advancing scRNA-Seq in primary human cells with our targeted sequencing (TA-Seq) platform! Key insights: • TA-Seq uses 10K reads/cell vs. 50K reads/cell for WTA • Low-abundance mRNAs are detected more effectively with TA-Seq myllia.com

We will be at #AACR25 in Chicago, USA Poster presentation: "A compressed genome-wide CROP-Seq screen to dissect the polarization of THP-1-derived macrophages" 🎯 When: Sunday, April 27 from 2.00 - 5.00 PM EST 🎯 Poster: LB043, Section 52 myllia.com #CRISPR

Looking forward to representing Myllia Biotechnology at the #SwissBiotechDay 2025 in Basel and discussing drug target ID/validation powered by single-cell CRISPR screens in primary human cells! 🎯 Explore Myllia's platform: myllia.com 📩 Contact: [email protected]

It's about one month to go until BIO US 2025 in Boston! Are you attending as well? If so, please reach out to our CSO Tilmann Bürckstümmer and our BD Manager Henrik Schmidt who will be attending #BIO2025 from June 16-19, 2025. Contact us via: 📩 [email protected] 📰 myllia.com

Compressed CROP-Seq screens enable functional genomics at scale: At Myllia Biotechnology, we are pushing the limits of #CRISPR screening with compressed genome-wide screens — a powerful method for dissecting cellular states and boosting screening capacity without compromising resolution!

Myllia Biotechnology launched VISTA for genome-wide #CRISPR screens enabling identification of novel drug targets across immune-related diseases. Ultima is enabling with high throughput and low-cost #sequencing on #UG100. Link to PR: biopharmadive.com/press-release/…

🧬 Join Myllia Biotechnology at #FOCIS2025 in Boston! We’re excited to share that our colleague Sumit Pawar will be presenting our latest work on the VISTA™ platform at #FOCIS25 📍 Poster: Th146 📅 Date: Thursday, June 26, 2025 myllia.com

🔬 Wrapping up an exciting week at #FOCIS2025 in Boston! We were thrilled to have Sumit Pawar, Associate Director of R&D at Myllia Biotechnology, present our latest research on the VISTA™ platform! 📩 Interested in partnering with Myllia? Reach out to us at [email protected]

🧬 Unlocking target discovery in primary human dendritic cells with VISTA™ At Myllia Biotechnology, we’re enabling high-throughput functional genomics in primary immune cells. Our VISTA™ platform combines pooled CRISPRi with scRNA-Seq to map gene function at scale! E: [email protected]